Artivion, Inc. (NYSE:AORT) Sees Large Increase in Short Interest

Artivion, Inc. (NYSE:AORT) was the target of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 3,220,000 shares, an increase of 7.3% from the October 31st total of 3,000,000 shares. Based on an average daily trading volume, of 223,200 shares, the days-to-cover ratio is currently 14.4 days. Currently, 8.2% of the company’s stock are sold short.

Insider Activity at Artivion

In related news, CAO Amy Horton sold 12,430 shares of Artivion stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total transaction of $325,417.40. Following the sale, the chief accounting officer now owns 139,989 shares of the company’s stock, valued at $3,664,912.02. The trade was a 8.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 8.10% of the company’s stock.

Hedge Funds Weigh In On Artivion

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Artivion by 1.3% during the first quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock worth $56,388,000 after purchasing an additional 33,982 shares during the period. First Eagle Investment Management LLC raised its stake in Artivion by 4.9% during the second quarter. First Eagle Investment Management LLC now owns 598,148 shares of the company’s stock worth $15,342,000 after acquiring an additional 27,906 shares during the period. Tidal Investments LLC bought a new position in Artivion in the first quarter worth about $257,000. Quest Partners LLC boosted its stake in Artivion by 2,481,700.0% in the third quarter. Quest Partners LLC now owns 24,818 shares of the company’s stock valued at $661,000 after acquiring an additional 24,817 shares during the period. Finally, Sio Capital Management LLC acquired a new stake in shares of Artivion during the 3rd quarter worth approximately $3,226,000. 86.37% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

AORT has been the topic of a number of analyst reports. Stifel Nicolaus lifted their target price on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, September 13th. JMP Securities started coverage on Artivion in a research report on Wednesday, October 23rd. They issued an “outperform” rating and a $33.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and set a $30.00 price target on shares of Artivion in a research report on Friday, September 27th. Finally, Oppenheimer upped their price target on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Artivion currently has an average rating of “Buy” and a consensus price target of $31.00.

Artivion Trading Up 0.3 %

NYSE:AORT opened at $29.62 on Tuesday. The company has a market cap of $1.24 billion, a PE ratio of -1,481.00 and a beta of 1.75. The business’s 50 day moving average is $27.09 and its two-hundred day moving average is $25.86. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. Artivion has a 52 week low of $16.48 and a 52 week high of $30.00.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.